Novartis Presents New Data at EULAR and WCD Further Demonstrating its Leadership in Severe Long-Term Inflammatory and Skin Conditions
![](/46/pdcnewsitem/03/45/66/FUgFM9NTmtrfylR.jpg)
Novartis has announced that important new data will be presented on secukinumab in ankylosing spondylitis (AS) at the forthcoming European League Against Rheumatism 2015 Annual Scientific Meeting (EULAR), 10–13 June in Rome, Italy. In addition, new data on Cosentyx (secukinumab) in difficult-to-treat psoriasis of the palms, soles and nails, and on Xolair (omalizumab) in Chronic Spontaneous Urticaria, will be presented at the 23rd World Congress of Dermatology (WCD), from 8–13 June in Vancouver, Canada. In total there will be five oral presentations and 32 posters from Novartis at these leading congresses.
"Patients with long-term inflammatory joint and skin conditions are too often living with debilitating physical and psychological effects of their disease," said Vasant Narasimhan, Global Head of Development, Novartis Pharmaceuticals. "We are excited to present further new data on secukinumab for ankylosing spondylitis, Cosentyx in psoriasis of the palms, soles and nails, and Xolair in Chronic Spontaneous Urticaria to address the significant unmet needs for these patients."
At the EULAR congress, data from the pivotal Phase III MEASURE 2 study will demonstrate that secukinumab improves the signs and symptoms of AS disease activity through one year of treatment, confirming previous one-year data from the MEASURE 1 study. AS is a long-term, painful and progressively debilitating inflammatory disease that leads to excessive formation of new bone, particularly in the joints of the spine, which can fuse together. There are limited therapeutic options available to people with AS and there is a significant unmet need for new treatment options.
Highlights of dermatology data at WCD include results of Cosentyx in difficult-to-treat and debilitating types of psoriasis of the palms and soles (palmoplantar), and nails. Palmoplantar and nail psoriasis have a more severe impact on patients than psoriasis that is limited to other parts of the body. Results showing quality of life improvements in Xolair-treated patients with Chronic Spontaneous Urticaria (CSU), a condition characterized by persistent itching, swelling and rash, and which is known as Chronic Idiopathic Urticaria (CIU) in the US and Canada, will also be presented at the congress. Xolair is the first and only therapy approved to treat CSU patients with inadequate responses to H1-antihistamines.
Cosentyx is the approved brand name for secukinumab in psoriasis. Secukinumab is not currently approved in AS or psoriatic arthritis (PsA).
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance